BRCA2 and leukemia: Small studies have reported conflicting data as to whether women with a single inherited mutation in BRCA1 or BRCA2 experience excess hematologic toxicity during cytotoxic chemotherapy.10, 11, 12 Reported toxicities included more frequent dose‐limiting neutropenia and neutropenic fever, cases of therapy‐related leukemia, and lower baseline blood counts.